Technical Analysis for CGEN - Compugen Ltd.

Grade Last Price % Change Price Change
grade D 3.17 0.96% 0.03
CGEN closed up 0.96 percent on Friday, January 18, 2019, on 65 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CGEN trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 17 50 DMA Support Bullish 0.96%
Jan 17 MACD Bullish Centerline Cross Bullish 0.96%
Jan 17 Wide Bands Range Expansion 0.96%
Jan 17 Overbought Stochastic Strength 0.96%
Jan 17 Up 3 Days in a Row Strength 0.96%
Jan 16 Crossed Above 50 DMA Bullish 6.02%

Older signals for CGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.
Is CGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.0
52 Week Low 2.0
Average Volume 155,684
200-Day Moving Average 3.4179
50-Day Moving Average 2.9855
20-Day Moving Average 2.627
10-Day Moving Average 2.899
Average True Range 0.2031
ADX 20.2
+DI 27.313
-DI 17.3682
Chandelier Exit (Long, 3 ATRs ) 2.5707
Chandelier Exit (Short, 3 ATRs ) 2.6093
Upper Bollinger Band 3.2508
Lower Bollinger Band 2.0032
Percent B (%b) 0.94
BandWidth 47.491435
MACD Line 0.0422
MACD Signal Line -0.0512
MACD Histogram 0.0935
Fundamentals Value
Market Cap 162.09 Million
Num Shares 51.1 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -4.73
Price-to-Sales 1330.24
Price-to-Book 3.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.34
Resistance 3 (R3) 3.32 3.25 3.31
Resistance 2 (R2) 3.25 3.21 3.26 3.30
Resistance 1 (R1) 3.21 3.18 3.23 3.23 3.29
Pivot Point 3.14 3.14 3.15 3.15 3.14
Support 1 (S1) 3.10 3.10 3.12 3.12 3.05
Support 2 (S2) 3.03 3.07 3.04 3.04
Support 3 (S3) 2.99 3.03 3.03
Support 4 (S4) 3.01